RecruitingAlzheimer Disease
Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.
Sponsor: Washington University School of Medicine
You may qualify if…
- ✓ Male or Female, any race
- ✓ Age ≥ 18 years
- ✓ Healthy volunteers or volunteers with Alzheimer's disease
You may not qualify if…
- ✕ Has hypersensitivity to 18F-Fluselenamyl or any of its excipients ;
- ✕ Has hypersensitivity to 11C-PIB or any of its excipients ;
- ✕ Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent ;
- ✕ Unwilling or unable to undergo PET scans tracer injections ;
- ✕ Unwilling or unable to undergo MRI (Aim 2 and Aim 3)
- ✕ Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., renal or liver failure, advanced cancer);
- ✕ Women who are currently pregnant or breast-feeding;
- ✕ Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1.
Where it's recruiting
Missouri
St Louis
Source: ClinicalTrials.gov · NCT06439992 · last updated 2026-06-09